Manuel Ruh

ORCID: 0000-0003-1815-3024
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • Biomedical Ethics and Regulation
  • Virus-based gene therapy research
  • Immunotherapy and Immune Responses
  • Mesenchymal stem cell research
  • Cancer Cells and Metastasis
  • Cancer-related gene regulation
  • Neonatal Respiratory Health Research
  • MicroRNA in disease regulation
  • Nutrition, Genetics, and Disease
  • Tissue Engineering and Regenerative Medicine
  • Peptidase Inhibition and Analysis
  • Histone Deacetylase Inhibitors Research
  • Metabolomics and Mass Spectrometry Studies
  • Bioinformatics and Genomic Networks
  • Cancer-related molecular mechanisms research
  • RNA Research and Splicing

Immatics Biotechnologies (Germany)
2023

Friedrich-Alexander-Universität Erlangen-Nürnberg
2015-2021

University Children's Hospital Tübingen
2015

University of Tübingen
2010-2015

Research Article14 April 2015Open Access Source Data ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat Simone Meidhof Department of General and Visceral Surgery, University Freiburg Medical Center, Freiburg, Germany Spemann Graduate School Biology Medicine (SGBM), Albert Ludwigs Faculty Biology, Search for more papers this author Brabletz Experimental I, Nikolaus-Fiebiger-Center Molecular Medicine, FAU Erlangen-Nürnberg, Erlangen, Waltraut...

10.15252/emmm.201404396 article EN cc-by EMBO Molecular Medicine 2015-04-14

Mesenchymal stromal cells (MSC) can be isolated from different tissues. They are capable of differentiating in vitro, for example, to osteoblasts, chondrocytes, or adipocytes. In contrast CD34 hematopoietic stem cells, a distinct MSC-defining antibody is not available. Further, lineage-defining antigens such as CD3 CD20 known. contrast, MSC-derived lineage-associated cell surface markers far being established. We therefore investigated expression on human term placenta-derived MSC (pMSC)...

10.1089/scd.2010.0308 article EN Stem Cells and Development 2010-11-03

Mesenchymal stromal cells (MSCs) are multipotent that can be differentiated in vitro into a variety of cell types, including adipocytes or osteoblasts. Our recent studies indicated high expression CD146 on MSCs from bone marrow correlates with their robust osteogenic differentiation potential. We therefore investigated if the placenta similar The were isolated specifically endometrial and fetal parts human term expanded separate cultures compared as controls. surface antigens was by flow...

10.1089/scd.2014.0465 article EN Stem Cells and Development 2015-03-06

Osteosarcoma is an often-fatal mesenchyme-derived malignancy in children and young adults. Overexpression of EMT-transcription factors (EMT-TFs) has been associated with poor clinical outcome. Here, we demonstrated that the EMT-TF ZEB1 able to block osteoblastic differentiation normal bone development as well osteosarcoma cells. Consequently, overexpression characterizes poorly differentiated, highly metastatic subgroups its depletion induces frequently silencing imprinted DLK-DIO3 locus,...

10.1002/path.5659 article EN The Journal of Pathology 2021-03-06

Abstract Mesenchymal stromal cells (MSCs) do not express a unique definite epitope or marker gene. As such, minimal criteria were recently established for defining multipotent MSC. These include expression of CD73, CD90, CD105, and lack hematopoietic expression. However, we detected binding CD14 antibody on bone marrow‐ placenta‐derived MSC investigated the staining antibodies these in more detail. The isolated from human marrow placenta tissue, expanded, characterized by quantitative...

10.1002/cyto.a.21073 article EN Cytometry Part A 2011-07-06

Abstract IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tumors expressing ≥1 of 8 predefined targets underwent leukapheresis. Endogenous specific for up to 4 were primed and expanded in vitro. Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion low-dose...

10.1158/2326-6066.cir-22-0444 article EN Cancer Immunology Research 2023-05-12

Background Platforms like tranSMART assist researchers in analyzing clinical and corresponding omics data. Usability is an important, yet often overlooked, factor affecting the adoption meaningful use. Analyses on specific needs of translational considerations about application such platforms for education are rare. Objectives The aim this study was to test whether can be used how well medical students professional handle it; identify which kind researchers—in terms skills, experienced...

10.4338/aci-2017-05-ra-0085 article EN cc-by-nc-nd Applied Clinical Informatics 2017-01-01
Coming Soon ...